相似文献
1
Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".
Drugs Aging. 2021 Jun;38(6):539-541. doi: 10.1007/s40266-021-00856-4. Epub 2021 Apr 19.
2
Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".
Drugs Aging. 2021 Jun;38(6):535-537. doi: 10.1007/s40266-021-00857-3. Epub 2021 Apr 19.
3
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Drug Saf. 2018 Jul;41(7):645-653. doi: 10.1007/s40264-018-0651-5.
4
Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Br J Clin Pharmacol. 2022 Sep;88(9):4180-4190. doi: 10.1111/bcp.15361. Epub 2022 May 2.
5
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2.
6
Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Drug Saf. 2020 Sep;43(9):881-891. doi: 10.1007/s40264-020-00958-9.
7
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Ann Rheum Dis. 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.
8
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Drug Saf. 2021 Aug;44(8):889-897. doi: 10.1007/s40264-021-01082-y. Epub 2021 Jun 13.
9
Thromboembolism and Janus Kinase Inhibitors.
Drug Saf. 2020 Sep;43(9):831-833. doi: 10.1007/s40264-020-00973-w.
10
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Expert Rev Clin Immunol. 2022 Mar;18(3):233-244. doi: 10.1080/1744666X.2022.2039630. Epub 2022 Feb 17.
本文引用的文献
1
Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".
Drugs Aging. 2021 Jun;38(6):535-537. doi: 10.1007/s40266-021-00857-3. Epub 2021 Apr 19.
2
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Int J Mol Sci. 2021 Feb 28;22(5):2449. doi: 10.3390/ijms22052449.
3
Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
Pharmacotherapy. 2020 Dec;40(12):1248-1264. doi: 10.1002/phar.2472. Epub 2020 Nov 16.
4
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Lupus Sci Med. 2020 Oct;7(1). doi: 10.1136/lupus-2020-000424.
5
Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding.
Haematologica. 2020 Aug;105(8):2020-2031. doi: 10.3324/haematol.2019.235994. Epub 2020 Jun 18.
6
Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Drug Saf. 2020 Sep;43(9):881-891. doi: 10.1007/s40264-020-00958-9.
7
Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk.
Drugs Aging. 2020 Aug;37(8):551-558. doi: 10.1007/s40266-020-00775-w.
8
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
J Clin Pharmacol. 2020 Feb;60(2):188-197. doi: 10.1002/jcph.1513. Epub 2019 Aug 25.
9
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.
10
Clonal hematopoiesis in patients with rheumatoid arthritis.
Blood Cancer J. 2018 Jul 26;8(8):69. doi: 10.1038/s41408-018-0107-2.
Zotero 插件